Show 1436: Why Mosquitoes Bite You and How to Outsmart Them

The People's Pharmacy

Joe and Terry Graedon

Health & Fitness, Medicine, Kids & Family, Alternative Health

4.5 • 934 Ratings

🗓️ 26 June 2025

⏱️ 73 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

In this episode, Joe & Terry speak with two scientists studying mosquito preferences. Why are some people mosquito magnets while others barely get bitten? A range of factors influences mosquito behavior and may explain why mosquitoes bite you and leave your neighbor alone. Learn how to outsmart them. You could listen through your local public […]

Transcript

Click on a timestamp to play from that location

0:00.0	I'm Joe Graydon.
0:01.5	And I'm Terry Graydon.
0:03.0	Welcome to this podcast of the People's Pharmacy.
0:06.1	You can find previous podcasts and more information on a range of health topics at
0:11.5	People's Pharmacy.com.
0:14.3	Are you a mosquito magnet?
0:16.6	Some people just seem to get bitten more often.
0:19.4	How do mosquitoes choose their victims?
0:22.4	This is the People's Pharmacy with Terry and Joe Graydon.
0:31.5	To find out why mosquitoes bite some people rather than others, we're talking with two scientists who study mosquito behavior.
0:41.3	Some experts state that mosquitoes are the deadliest animals on the planet. Will Americans soon be at risk because of climate change?
0:49.3	What can we do to prevent mosquitoes from finding us? Besides Diet, what else works as an effective repellent?
0:57.2	Coming up on the People's Pharmacy, why mosquitoes bite the Food and Drug Administration recently approved a new medicine to prevent HIV infection.
1:23.5	There are already some preventive measures that can keep people from contracting the infection that leads to AIDS.
1:30.0	Doctors call them pre-exposure prophylaxis or prep.
1:34.0	The newly approved medicine called Lena Capovir requires just two injections a year.
1:41.4	Gilead, the company that developed LenaCapovir, has experience with other drugs against
1:46.7	HIV and AIDS. The medication did surprisingly well in pre-approval clinical trials. Young women in
1:54.5	Uganda and South Africa got 100% protection from the virus, an outcome that's almost unheard of in previous research.
2:04.2	The issue ahead is how many people at risk for AIDS will be able to get the benefits of the drug.
2:12.0	Gilead plans to sell it as ESTugo at a price of more than $28,000 a year. This will put it out of reach for many
2:20.7	people in the U.S., especially as Medicaid coverage is cut. In addition, people in poorer countries
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Joe and Terry Graedon, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Joe and Terry Graedon and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.